Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for cancer and other challenging diseases. This news hub provides investors and industry professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases, clinical trial progress reports, and partnership announcements in one centralized location. Our curated collection includes updates on key pipeline assets like cemsidomide and CFT1946, collaboration developments with Biogen and Merck, and financial disclosures essential for informed decision-making.
Discover comprehensive coverage of C4 Therapeutics' innovative TORPEDO® platform advancements, protein degrader research breakthroughs, and participation in major medical conferences. All content is sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page to stay informed about CCCC's progress in developing novel therapies that address drug resistance and undruggable targets through targeted protein degradation science. Check regularly for new developments in this cutting-edge area of biopharmaceutical research.
C4 Therapeutics (Nasdaq: CCCC) announced promising early data from its Phase 1/2 trial of CFT7455, a targeted protein degrader aimed at treating multiple myeloma and non-Hodgkin's lymphomas. The trial demonstrated significant drug activity, with some patients showing reductions in serum free light chains by up to 78%. However, dose-limiting toxicities were noted, including Grade 4 neutropenia. The trial aims to optimize dosing to enhance the therapeutic index as patient enrollment continues. A conference to discuss these findings is scheduled for today.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has appointed Utpal Koppikar as an independent board member and chair of the Audit Committee. Koppikar, currently CFO at Atara Biotherapeutics, brings extensive financial expertise and leadership in the biotechnology sector. The appointment aims to enhance corporate governance and support C4T's growth strategies in targeted protein degradation. Following this change, Dr. Elena Prokupets has retired from the board. C4T is advancing its novel degrader medicines using its TORPEDO® platform to transform patient care.
C4 Therapeutics (Nasdaq: CCCC) announced that the FDA has granted orphan drug designation to CFT8634 for treating soft tissue sarcoma. This designation benefits drug development for rare diseases affecting fewer than 200,000 people in the U.S., offering financial incentives and potential market exclusivity. CFT8634 targets BRD9, considered an 'undruggable' target, demonstrating efficacy in preclinical models. The company aims to begin Phase 1/2 trials in the first half of 2022, addressing a critical need as current treatment options for synovial sarcoma patients are limited.
C4 Therapeutics (Nasdaq: CCCC) has announced that its clinical data from the ongoing Phase 1/2 trial of CFT7455 will be presented as a late-breaker poster at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. This includes three oral presentations on the novel IKZF1/3 degrader, along with additional preclinical data on CFT8634 and CFT1946. An investor webcast is scheduled for April 8, 2022, at 2 PM ET to discuss these findings, showcasing the company's commitment to advancing targeted protein degradation in oncology.
C4 Therapeutics reported significant advancements and financial results for 2021, including total revenue of $45.8 million, up from $33.2 million in 2020, primarily due to collaboration agreements. Despite a net loss of $83.9 million, the net loss per share improved to $1.82 from $5.83. The company anticipates its cash reserves of $451.5 million will sustain operations through 2024. Upcoming presentations at the AACR Annual Meeting will showcase clinical data on the CFT7455 trial for hematologic malignancies and pre-clinical data on novel candidates.
C4 Therapeutics (Nasdaq: CCCC) announced key milestones for 2022, including expected initial data for CFT7455, a novel degrader for multiple myeloma and lymphomas. The FDA granted IND clearance for CFT8634, allowing the initiation of its Phase 1 trial in synovial sarcoma. Additionally, CFT1946, targeting BRAF V600X, will enter trials in 2H 2022. With approximately $450 million in cash expected to last until late 2024, the company is poised for growth and innovation.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. EST. This conference emphasizes the company's innovative approach to developing small-molecule medicines that selectively degrade disease-causing proteins.
The live webcast can be viewed on the company's website, with a replay available for two weeks post-event. C4 Therapeutics focuses on targeted protein degradation to improve treatment options for cancer and other diseases.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, has been included in the NASDAQ Biotechnology Index, effective December 20, 2021. This index tracks notable biotechnology and pharmaceutical companies listed on NASDAQ, requiring eligibility criteria such as minimum market capitalization and average daily trading volume of 100,000 shares. C4 Therapeutics focuses on developing drugs that selectively degrade disease-causing proteins, offering advantages like reduced drug resistance and side effects. The company aims to target cancer and other diseases.
C4 Therapeutics (Nasdaq: CCCC) reported Q3 2021 revenue of $8.5 million, slightly up from $8.4 million YoY. R&D expenses rose to $24.3 million from $23.9 million, driven by pre-clinical costs. G&A expenses surged to $8.5 million from $2.9 million, mainly due to stock-based compensation and professional fees. A net loss of $24.7 million was recorded, with net loss per share at $0.51. The company anticipates submitting an IND application for CFT8634 by year-end 2021 and aims to deliver four clinical programs by the end of 2022.
C4 Therapeutics (Nasdaq: CCCC) reported significant advancements in their clinical programs and financials for Q2 2021. They initiated the Phase 1/2 trial of CFT7455 for hematologic malignancies and received Orphan Drug Designation from the FDA for this therapy. The company reported Q2 revenue of $9.8 million, a slight increase from $9.7 million in the previous year, and a net loss of $22.6 million, up from $10.8 million. A successful public offering yielded $180.8 million, bolstering cash reserves to approximately $499 million by June 30, 2021, supporting their ambitious clinical development plans.
